Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.48 |
| ▸ | CDC25B | P30305 | 8/20 | 0.48 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.48 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.48 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | GJB2 | P29033 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26447373 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL10259814 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL6895176 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL2989107 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL14616676 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL19204220 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL6574752 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL13129824 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL15975379 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL2287945 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695319-B2 | Glucose conjugates of triptolide, analogs and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-06-30 | — | — | US | claimed |
| US-11692004-B2 | Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof | JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| WO-2020038279-A1 | SUBSTITUTED PYRAZOLE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 天津谷堆生物医药科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
| US-10087242-B2 | Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X | INSTITUT PASTEUR (FR) | 2018-10-02 | — | — | US | disclosed |
| CN-104372052-A | Method for preparing glucoside compounds by combination of chemical process and enzyme process | UNIV HUAZHONG SCIENCE TECH | 2015-02-25 | — | — | CN | disclosed |
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | INSTITUT PASTEUR (FR) | 2015-02-19 | — | — | US | disclosed |
| US-8815239-B2 | Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X | INSTITUT PASTEUR (FR) | 2014-08-26 | — | — | US | disclosed |
| US-20100239584-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | INSTITUT PASTEUR (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087242-B2 | Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X | ST3GAL3, SI, STT3A | NT5E 2128/4885PTPN1 733/4885CDC25B 2851/4885 |
| US-20100239584-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | ST3GAL3, SI, STT3A | NT5E 2128/4885PTPN1 733/4885CDC25B 2851/4885 |
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | ST3GAL3, SI, STT3A | NT5E 2128/4885PTPN1 733/4885CDC25B 2851/4885 |
| US-11692004-B2 | Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof | FARS2, GOT2, HADHB | NT5E 4320/4885PTPN1 4216/4885CDC25B 4088/4885 |
| US-10695319-B2 | Glucose conjugates of triptolide, analogs and uses thereof | SLC2A8, SLC2A4, SLC2A1 | NT5E 698/4885PTPN1 596/4885CDC25B 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.